Lilly’s oral obesity pill

Eli Lilly’s new obesity pill Foundayo is giving the weight-loss drug market something it has mostly lacked: a once-daily tablet instead of a shot. (fda.gov) The Food and Drug Administration approved Foundayo, the brand name for orforglipron, on April 1 for adults with obesity or adults who are overweight and have at least one weight-related condition. The label says it should be used with a reduced-calorie diet and increased physical activity. (fda.gov) Foundayo is a glucagon-like peptide-1, or GLP-1, drug, a class that mimics a gut hormone that helps people feel fuller and eat less. Lilly said this pill can be taken any time of day without food or water restrictions, unlike earlier oral GLP-1 regimens with tighter dosing rules. (lilly.com; pharmexec.com) In Lilly’s 72-week ATTAIN-1 study, adults on the highest dose lost an average of 27.3 pounds, or 12.4% of body weight, according to the company’s approval announcement. The company also said prescriptions were accepted immediately through LillyDirect, with shipping that began April 6. (lilly.com; usatoday.com) Early demand arrived fast. Analysts citing IQVIA data said Foundayo was prescribed 1,390 times in the U.S. in its first week on the market, with the count covering the week ended April 10. (pharmexec.com; reuters.com) Lilly released new trial results on April 16 saying Foundayo met cardiovascular safety goals in the Phase 3 ACHIEVE-4 study, which enrolled adults with type 2 diabetes and higher cardiovascular risk. The Food and Drug Administration’s approval letter also requires Lilly to finish that trial and submit more safety data on major adverse cardiovascular events and possible liver injury. (lilly.com; fda.gov) The approval moved unusually fast. The Food and Drug Administration said Foundayo was cleared 50 days after filing and 294 days before its January 20, 2027 user-fee deadline under the agency’s Commissioner’s National Priority Voucher pilot. (fda.gov) The access problem is not the prescription pad. NPR reported this week that coverage for obesity drugs is getting more restrictive, and GoodRx found that from 2025 to 2026 about 12 million people lost coverage for Zepbound and another 12 million lost coverage for Wegovy. (npr.org; goodrx.com) GoodRx said more than 109 million people now lack commercial coverage for Zepbound and more than 41 million lack it for Wegovy. Lilly says Foundayo starts at $25 a month for commercially insured patients and $149 for self-pay through LillyDirect, but those prices do not settle whether employer plans and insurers will broadly cover it. (goodrx.com; lilly.com) The pill’s side effects look familiar to anyone who has followed this drug class. The FDA label warns about thyroid C-cell tumors and lists nausea, vomiting and diarrhea as more common during dose escalation before easing over time. (fda.gov) Foundayo gives Lilly a tablet to sell into a market built on injections, but the next test is less about chemistry than coverage. A drug that is easier to take still has to be paid for. (fda.gov; npr.org)